Trial record 1 of 1 for:    "chylomicron retention disease"
Previous Study | Return to List | Next Study

Belgian Screening Project for the Detection of Anderson-Fabry Disease in Hypertrophic Cardiomyopathy

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
University Hospital, Ghent
ClinicalTrials.gov Identifier:
NCT01198899
First received: August 31, 2010
Last updated: January 11, 2012
Last verified: January 2012
  Purpose

The purpose of this study is to determine the prevalence of Fabry mutations in patients with left ventricular hypertrophy (moderate to severe), as measured by echocardiography.This study is a screening study


Condition Intervention
Left Ventricular Hypertrophy
Other: blood sampling

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Belgian Screening Project for the Detection of Anderson-Fabry Disease in Hypertrophic Cardiomyopathy

Resource links provided by NLM:


Further study details as provided by University Hospital, Ghent:

Primary Outcome Measures:
  • Determination of the prevalence of Fabry mutations in patients with left ventricular hypertrophy (moderate to severe), as measured by echocardiography [ Time Frame: At baseline T0 ] [ Designated as safety issue: No ]
    patients with left ventricular hypertrophy will be screened for Fabry mutations, and results will be communicated within four months


Enrollment: 540
Study Start Date: July 2009
Study Completion Date: August 2011
Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
left ventricular hypertrophy
Patients with left ventricular hypertrophy will be used.
Other: blood sampling
Blood sampling will be used.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

patients with left ventricular hypertrophy

Criteria

Inclusion Criteria:

  • All patients over 18 years undergoing a routine echocardiography in the participating hospitals
  • Both genders will be considered.
  • Patients can be included if on 2D echocardiography the maximal septal wall thickness > 13 mm and/or the posterior wall thickness > 13 mm. The limit for inclusion is kept relatively low to detect early forms of Fabry cardiomyopathy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01198899

Locations
Belgium
AZ Imelda
Bonheiden, Belgium
AZ Sint-Blasius
Dendermonde, Belgium
Maria Middelares
Gent, Belgium
AZ Sint-Lucas
Gent, Belgium
University Hospital Ghent
Ghent, Belgium
Jan Yperman Ziekenhuis
Ieper, Belgium
AZ Oostkust
Knokke-Heist, Belgium
ZOL
Limburg, Belgium
AZ Zusters van Barmhartigheid
Ronse, Belgium
Sponsors and Collaborators
University Hospital, Ghent
Investigators
Principal Investigator: Raymond Vanholder, MD, PhD University Hospital Ghent, Belgium
  More Information

Additional Information:
No publications provided by University Hospital, Ghent

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: University Hospital, Ghent
ClinicalTrials.gov Identifier: NCT01198899     History of Changes
Other Study ID Numbers: 2009/035
Study First Received: August 31, 2010
Last Updated: January 11, 2012
Health Authority: Belgium: Ethics Committee

Keywords provided by University Hospital, Ghent:
Fabry-Anderson disease
gen mutation
left ventricular hypertrophy

Additional relevant MeSH terms:
Fabry Disease
Cardiomyopathy, Hypertrophic
Hypertrophy
Hypertrophy, Left Ventricular
Cardiomyopathies
Sphingolipidoses
Lysosomal Storage Diseases, Nervous System
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Genetic Diseases, X-Linked
Genetic Diseases, Inborn
Metabolism, Inborn Errors
Lipidoses
Lipid Metabolism, Inborn Errors
Lysosomal Storage Diseases
Metabolic Diseases
Lipid Metabolism Disorders
Heart Diseases
Cardiovascular Diseases
Aortic Stenosis, Subvalvular
Aortic Valve Stenosis
Heart Valve Diseases
Pathological Conditions, Anatomical
Cardiomegaly

ClinicalTrials.gov processed this record on July 22, 2014